CCL2 and non-small cell lung carcinoma: IL-12 treatment of NBEC reduced significantly their ability to release some cytokines/chemokines that have been shown to be involved in NSCLC angiogenesis, progression and spreading [31]–[36] such as, for example, MCP-1/CCL2 and IL-6 [37].